

OCTOBER 2025
Marketing communication

INVESTMENT OBJECTIVE

To achieve capital appreciation on an absolute and relative basis over the medium to long-term horizon through investment in Swiss equities with a focus on innovative companies that are leaders in their markets profile.

PORTFOLIO REVIEW

October marked the beginning of the third quarter corporate earnings season. While results vary across sectors and companies, as might be expected, one common theme is emerging: the burden of the new US tariffs on Swiss exports. The impact is proving more negative than expected, and to date, although diplomatic discussions continue behind the scenes, no tangible results have yet been achieved by the Swiss government.

The Protea BAM Swiss Equities fund closed the month up 1.2%, very close to the SPI (+1.4%). The main contributors to relative performance were Straumann (+19%), Sandoz (+13%), VAT (+11%) and Galderma (+7%).

After a difficult year on the stock market to date, dental implant manufacturer Straumann staged a spectacular rebound, posting its best monthly performance since early 2021. These gains, supported also by short covering, followed the release of stronger-than-expected quarterly results, restoring investor confidence in the company's growth profile. Unlike its competitors, and despite a gloomy macroeconomic environment, Straumann posted very dynamic organic growth (+8.3%) in the third quarter. The market was also reassured by signs of improvement in North America (27% of sales), a region that had lost its driving role but is now benefiting from a gradual decline in interest rates. Straumann's European business continues to record double-digit growth, despite challenging base effects. The only cloud on the horizon remains China, which is gearing up for the second wave of its national volume-based procurement (VBP) programme, launched in 2018. This group purchasing system guarantees very high volumes to manufacturers in exchange for significantly reduced prices, which has already led to price reductions of up to 90% for certain medical devices. A further price cut is expected in January, but it should be more moderate, around 10% for Straumann. Ahead of this, distributors are reducing their stocks and some patients are postponing their treatments. The first cycle enabled Straumann to gain volume without sacrificing profitability; there is currently no reason to believe that this second cycle will be any different.

Among the sharpest monthly decliners figure industrial companies whose business is not directly exposed to current popular themes such as artificial intelligence or electrification, notably Sika (-11%), Burckhardt Compression (-10%) and Georg Fischer (-9%).

RISK & REWARD



FUND FACTS


Domicile	Luxembourg (UCITS)
Inception date	10 June 2021
Currency	CHF
Lead Manager	Anick Baud
Co-Manager	Florian Marini CFA, CMT
Fund size*	CHF 31 Millions
Liquidity (sub./red.)	Daily
Min. Investment	Instit.: 1 million CHF
Entry/exit fees	0.0% / 0.0%
Management fees	0.8%
Performance fees	20%
High Water Mark	Yes
Benchmark	MSCI Switzerland 10-40
ISIN	Instit.: LU2264701074
Bloomberg	Instit.: PRPSEIC LX

NAV Instit.: 103.94

* the total strategy size is CHF 65 millions

Not all the costs are presented, further information can be found in the prospectus or equivalent.

NET PERFORMANCE AND ANNUAL PERFORMANCE IN CHF



	Fund	MSCI Switzerland 10-40	+/-
1 Month	1.2%	1.7%	-0.5%
3 Months	0.2%	2.7%	-2.5%
YTD	8.8%	8.7%	0.1%
Since inception	3.9%	14.8%	-10.8%

Source: All data and graphs throughout the document from Bruellan.

Past performance may not be a reliable guide to future performance. All forms of investment involve risk.


The benchmark index is the MSCI Switzerland 10-40.

Please refer to the end of the document mentioned for performance comparison purposes.


STATISTICS

	Fund	MSCI Switzerland 10-40
Leading PE	21.7	17.8
EV/EBITDA	19.9	11.9
P/Book	6.1	1.9
Dividend Yield	2.0%	2.6%
ROE	28.9%	7.9%
Debt/Equity	58.0%	55.4%
Interest Coverage	14.8	8.4
Beta	1.0	1.0
Volatility	17.3%	13.5%

ALLOCATION BY MARKET CAP



ALLOCATION BY SECTOR



FUND COMPLEMENTARY DETAILS

Administrator	Fund Partner Solutions SA
Representative in Switzerland	FundPartner Solutions (Suisse) SA
Investment Manager	Bruellan SA
Paying agent in Switzerland	Banque Pictet & Cie SA
Auditor	Deloitte Audit SARL
Custodian	Bank Pictet & Cie (Europe) AG, Succursale de Luxembourg

TOP 10 HOLDINGS

	Sector	Weight
NESTLE SA-REG	Consumer Staples	9.6%
NOVARTIS AG-REG	Health Care	9.3%
ROCHE HOLDING AG-GENUSSCHEIN	Health Care	8.5%
BELIMO HOLDING AG-REG	Industrials	4.8%
CIE FINANCIERE RICHEMO-A REG	Consumer Discretionary	4.8%
GALDERMA GROUP AG	Health Care	4.5%
ZURICH INSURANCE GROUP AG	Financials	4.2%
LONZA GROUP AG-REG	Health Care	4.2%
ABB LTD-REG	Industrials	3.9%
GIVAUDAN-REG	Materials	3.8%
Total		57.7%
Total number of Holdings		25

CONTACT

BRUELLAN SA
Rue Pécolat 1
CH-1201 Genève
Tél: +41 22 817 18 55
bam@bruellan.ch

Disclaimer: Bruellan SA has a FINMA authorisation as a collective asset manager. This publication is a promotional document within the meaning of art. 68 LSFIn, it is not independent research. It is solely intended to provide information on the funds in question and does not constitute an offer to buy or sell, investment advice or a recommendation regarding investment or other decisions. The funds may be subject to sales restrictions applicable to certain countries or individuals. It is the responsibility of each investor to be aware of the terms and conditions applicable to each product. This publication is directed only at persons authorised to receive it under the regulations in force in their country of domicile.

The information contained herein is based on sources believed to be reliable. This is a marketing communication. Bruellan cannot guarantee its completeness and accuracy and accepts no liability for any damage that may result from actions taken on the basis of the information published in this document. The information reflects the situation on the day of publication. We have classified this product as 5 out of 7, which is a medium - high risk class. Please refer to the prospectus for more information on the specific risks relevant to this product not included in the summary indicator.

Investment decisions should always be made on the basis of a detailed source of information, in particular the fund prospectus. The prospectus, the articles of association, the key information document, the subscription form and the latest annual and semi-annual reports can be obtained (free of charge) from the Swiss representative, Fund Partner Solutions (Suisse) SA, 60, route des Acacias, 1211 Geneva. Please refer to the prospectus and information document of the fund before making any final investment decisions. You can obtain a summary of investors rights to the following link: <https://www.pictet.com/content/dam/www/documents/legal-and-notes/fundpartner-solutions/fps-summary-of-Investors-rights.pdf>. The decision to invest in the promoted fund should take into account all the characteristics or objectives of the promoted fund as described in its prospectus. Information on sustainability-related aspects provided in relation to the promoted fund could be found on the following link: <https://asset-services.group.pictet.com/asset-services/esg-disclosures?isin=LU1118008553>. Incorporation of extra-financial risks into the investment decision process may result in underweighting of profitable investments from the sub-fund's investment universe and may also lead the management of the sub-fund to underweight investments that will continue to perform. The Fund has been classified as a financial product subject to Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial sector (the "SFDR"). The Fund promotes, among other characteristics, environmental or social characteristics, or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices. Performance disclosures: the published performance represents past data. Past performance may not be a reliable guide to future performance. There is no guarantee that the same yields will be obtained in the future. The value and income of any of your investments may fluctuate with market conditions and may lose some or all its value. The fund may be affected by changes in currency exchange rates, which can have an adverse effect on the value or income of the fund. Future performance is also subject to taxation which depends on the personal situation of each investor and which may change in the future. : All performance data are based on net performance and take no account of commissions, fees or other costs charged when units are issued and redeemed.